EyePoint Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a proposed underwritten public offering of $150.0 million of common stock with a 30‑day underwriter option to purchase up to an additional $22.5 million. The company said proceeds are intended to advance clinical development of DURAVYU for wet AMD and DME, support earlier‑stage pipeline programs, and for general corporate purposes. J.P. Morgan, Jefferies, Citigroup, and Guggenheim are joint book‑running managers. The offering is subject to market conditions and will be made via a prospectus supplement to an effective Form S‑3 registration statement.

Positive

• $150.0M committed offering size
• Up to $22.5M additional underwriter option
• Proceeds earmarked to advance DURAVYU for wet AMD and DME

Negative

• Proposed offering may cause shareholder dilution
• Completion dependent on market conditions, not guaranteed

Insights

Capital Markets Strategist

EyePoint announced a dilutive underwritten common stock offering to raise $150 million plus a $22.5 million option to fund clinical and pipeline work.

EyePoint Pharmaceuticals is offering $150 million of common stock with a 30‑day option for up to $22.5 million, using net proceeds to advance DURAVYU development for wet AMD and DME and support earlier‑stage programs. The shares are being sold from the company’s shelf registration and the deal is led by major banks, indicating a standard capital‑markets execution.

The primary business mechanism here is straightforward: equity issuance to fund clinical and R&D activities. This reduces cash burn pressure but dilutes existing equity; completion depends on market conditions and final offering terms. Key risks include dilution magnitude, timing if market conditions delay the deal, and the possibility that raised funds may not cover all planned milestones.

Watch for the filed preliminary prospectus supplement for exact share count, price range, and use‑of‑proceeds breakdown; those items will clarify dilution and runway impact. Monitor near‑term announcements on pricing and allocation and milestone timelines for DURAVYU development over the next 6–18 months.

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. All of the shares are being offered by EyePoint. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $22.5 million of shares of EyePoint’s common stock at the public offering price, less the underwriting discount.

J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book running managers for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of DURAVYU™ for wet age related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as support its earlier stage pipeline development initiatives, and for general corporate purposes.

The securities described above to be issued and sold are being offered by the Company pursuant to an automatically effective shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission.

The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EyePoint

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data to date, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with data anticipated in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the timing and success of the proposed offering, the anticipated use of proceeds for the proposed offering, EyePoint’s clinical development plans and the expected timing thereof; and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes satisfaction of the customary closing conditions of the offering; delays in obtaining required stock exchange or other regulatory approvals; stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy; the timing, progress and results of the company’s clinical development activities; uncertainties and delays relating to the design, enrollment, completion and results of clinical trials; unanticipated costs and expenses; the company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the company’s product candidates; changes in the regulatory environment; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the company’s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts and the company’s ongoing discussions with the Department of Justice regarding a negotiated settlement of such matter; uncertainties regarding the FDA warning letter pertaining to the company’s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. More detailed information on these and additional factors that could affect EyePoint’s actual results are described in EyePoint’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What amount is EyePoint (EYPT) proposing to raise in the October 14, 2025 offering?

EyePoint announced a proposed underwritten offering of $150.0 million of common stock, with a 30‑day option for up to $22.5 million additional.

How does the EYPT offering plan to use the net proceeds from the October 14, 2025 raise?

Net proceeds are intended to fund clinical development of DURAVYU for wet AMD and DME, support earlier‑stage pipeline work, and for general corporate purposes.

Who are the lead underwriters for EyePoint's (EYPT) October 14, 2025 share offering?

J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book‑running managers.

Will EyePoint (EYPT) definitely complete the proposed $150M offering?

No. The company said the offering is subject to market conditions and there is no assurance as to whether or when it will be completed.

Could the size of EyePoint's (EYPT) offering change after October 14, 2025?

Yes. EyePoint granted underwriters a 30‑day option to buy up to an additional $22.5M, which would increase the offering size if exercised.